{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:46:29Z","timestamp":1791963989954,"version":"4.3.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12915-3","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:39:15Z","timestamp":1791826755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pituitary adenomas (PitNETs): molecular pathophysiology, targeted drug delivery strategies and clinical therapeutic outcomes"],"prefix":"10.1007","volume":"53","author":[{"given":"Abdul","family":"Shadab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hailat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"12915_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2025.102039","author":"N Wu","year":"2025","unstructured":"Wu N, Wu N, Wang N, Zhu Y (2025) Progress in the pathogenesis and treatment of pituitary neuroendocrine tumors (PitNETs): from molecular mechanisms to emerging therapies. Mol Cell Probes. https:\/\/doi.org\/10.1016\/j.mcp.2025.102039","journal-title":"Mol Cell Probes"},{"key":"12915_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310952","author":"A Derwich","year":"2023","unstructured":"Derwich A, Sykutera MA, Bromi\u0144ska B, Rubi\u015b B, Rucha\u0142a M, Sawicka-Gutaj N (2023) The role of activation of PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways in aggressive pituitary adenomas\u2014new potential therapeutic approach\u2014a systematic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241310952","journal-title":"Int J Mol Sci"},{"key":"12915_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.791633","author":"C Pivonello","year":"2022","unstructured":"Pivonello C, Patalano R, Negri M et al (2022) Resistance to dopamine agonists in pituitary tumors: molecular mechanisms. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.791633","journal-title":"Front Endocrinol"},{"key":"12915_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13313","author":"L Botelho","year":"2024","unstructured":"Botelho L, Dezonne R, Wildemberg LE, Miranda RL, Gadelha M, Andreiuolo F (2024) Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: a pathologist\u2019s perspective. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.13313","journal-title":"Brain Pathol"},{"key":"12915_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000514862","volume":"112","author":"A Spada","year":"2021","unstructured":"Spada A, Mantovani G, Lania A et al (2021) Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior. Neuroendocrinology 112:15\u201333. https:\/\/doi.org\/10.1159\/000514862","journal-title":"Neuroendocrinology"},{"key":"12915_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-025-02025-9","author":"F Martinez-Mendoza","year":"2025","unstructured":"Martinez-Mendoza F, Andonegui-Elguera S, Sosa-Eroza E et al (2025) Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-025-02025-9","journal-title":"Acta Neuropathol Commun"},{"key":"12915_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01796-x","author":"K Taniguchi-Ponciano","year":"2024","unstructured":"Taniguchi-Ponciano K, Hinojosa-Alvarez S, Hernandez-Perez J et al (2024) Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-024-01796-x","journal-title":"Acta Neuropathol Commun"},{"key":"12915_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1089\/ars.2024.0611","volume":"42","author":"L Xu","year":"2024","unstructured":"Xu L, Lei Z, Wang Q et al (2024) Androgen receptor mediates dopamine agonist resistance by regulating intracellular reactive oxygen species in prolactin-secreting pituitary adenoma. Antioxid Redox Signal 42:954\u2013972. https:\/\/doi.org\/10.1089\/ars.2024.0611","journal-title":"Antioxid Redox Signal"},{"key":"12915_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad171","author":"D Regazzo","year":"2023","unstructured":"Regazzo D, Avallone S, MacSweeney C et al (2023) A novel somatostatin receptor ligand for human ACTH- and GH-secreting pituitary adenomas. Eur J Endocrinol. https:\/\/doi.org\/10.1093\/ejendo\/lvad171","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"12915_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.mpsur.2023.10.005","volume":"42","author":"S Pillai","year":"2024","unstructured":"Pillai S, Debono M (2024) Physiology of the pituitary, thyroid, parathyroid and adrenal glands. Surg Infect (Larchmt) 42(4):209\u2013223. https:\/\/doi.org\/10.1016\/j.mpsur.2023.10.005","journal-title":"Surg Infect (Larchmt)"},{"key":"12915_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163950","author":"I Gesmundo","year":"2021","unstructured":"Gesmundo I, Granato G, Fuentes-Fayos A et al (2021) Antagonists of growth hormone-releasing hormone inhibit the growth of pituitary adenoma cells by hampering oncogenic pathways and promoting apoptotic signaling. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13163950","journal-title":"Cancers (Basel)"},{"key":"12915_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031447","author":"O Rogoza","year":"2022","unstructured":"Rogoza O, Megnis K, Kudrjavceva M, Geri\u0146a-B\u0113rzi\u0146a A, Rovite V (2022) Role of Somatostatin Signalling in Neuroendocrine Tumours. International J Molecular Scis. https:\/\/doi.org\/10.3390\/ijms23031447","journal-title":"International J Molecular Scis"},{"key":"12915_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s12020-025-04404-7","volume":"90","author":"AHA Tajuddin","year":"2025","unstructured":"Tajuddin AHA, Sukor N, Azizan E et al (2025) Tamoxifen for residual NF-PitNETs: A Proof-of-Concept study integrating receptor profiling, pilot trial, and target pathway analysis. Endocrine 90:863\u2013876. https:\/\/doi.org\/10.1007\/s12020-025-04404-7","journal-title":"Endocrine"},{"key":"12915_CR14","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.5c01123","author":"D Fan","year":"2025","unstructured":"Fan D, Wang Z, Yuan X et al (2025) Ru(II)-Photodynamic therapy suppresses nonfunctioning pituitary adenoma growth by targeting PI3K\/AKT\/p53 signaling. ACS Appl Bio Mater. https:\/\/doi.org\/10.1021\/acsabm.5c01123","journal-title":"ACS Appl Bio Mater"},{"key":"12915_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070898","author":"M Cai","year":"2022","unstructured":"Cai M, Park H, Yang E (2022) Nutraceutical interventions for post-traumatic stress disorder in animal models: a focus on the hypothalamic\u2013pituitary\u2013adrenal axis. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15070898","journal-title":"Pharmaceuticals (Basel)"},{"key":"12915_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1658592","author":"Y Muhammad","year":"2025","unstructured":"Muhammad Y (2025) Reproductive aging in biological females: mechanisms and immediate consequences. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2025.1658592","journal-title":"Front Endocrinol"},{"key":"12915_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115719","author":"S Serioli","year":"2023","unstructured":"Serioli S, Agostini L, Pietrantoni A et al (2023) Aggressive PitNETs and potential target therapies: a systematic review of molecular and genetic pathways. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242115719","journal-title":"Int J Mol Sci"},{"key":"12915_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/da\/9984291","author":"Q Li","year":"2025","unstructured":"Li Q, Ling Y, Gu L et al (2025) MicroRNAs as regulators of neuroinflammation in major depressive disorder. Depress Anxiety. https:\/\/doi.org\/10.1155\/da\/9984291","journal-title":"Depress Anxiety"},{"key":"12915_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/164_2023_666","author":"M Acosta-Mart\u00ednez","year":"2023","unstructured":"Acosta-Mart\u00ednez M (2023) Hypothalamic-Pituitary-Gonadal Axis Disorders Impacting Fertility in Both Sexes and the Potential of Kisspeptin-Based Therapies to Treat Them. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/164_2023_666","journal-title":"Handb Exp Pharmacol"},{"key":"12915_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010116","author":"A Milewska-Kranc","year":"2023","unstructured":"Milewska-Kranc A, \u0106wik\u0142a JB, Kolasi\u0144ska-\u0106wik\u0142a A (2023) The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors. Cancers. https:\/\/doi.org\/10.3390\/cancers16010116","journal-title":"Cancers"},{"key":"12915_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010065","author":"C Li","year":"2021","unstructured":"Li C, Huang B, Zhang Y (2021) Chinese herbal medicine for the treatment of depression: effects on the neuroendocrine-immune network. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14010065","journal-title":"Pharmaceuticals (Basel)"},{"key":"12915_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101056","volume":"73","author":"J Cheng","year":"2024","unstructured":"Cheng J, Xie W, Chen Y et al (2024) Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs. Drug resistance updates\u202f: reviews and commentaries in antimicrobial and anticancer chemotherapy 73:101056. https:\/\/doi.org\/10.1016\/j.drup.2024.101056","journal-title":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"12915_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1267\/ahc.23-00039","volume":"56","author":"I Nakazato","year":"2023","unstructured":"Nakazato I, Shiomi T, Oyama K, Matsuno A, Inomoto C, Osamura YR (2023) Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs. Acta Histochem Cytochem 56:121\u2013126. https:\/\/doi.org\/10.1267\/ahc.23-00039","journal-title":"Acta Histochem Cytochem"},{"key":"12915_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/dom.70256","volume":"28","author":"L Yang","year":"2025","unstructured":"Yang L, Guo N, Wang X et al (2025) Hypothalamic RASA1\/Ras\/AKT\/GnRH axis reprogramming mediates GLP\u20101RA\u2019s central rescue of PCOS HPG dysfunction. Diabetes 28:711\u2013727. https:\/\/doi.org\/10.1111\/dom.70256","journal-title":"Diabetes"},{"key":"12915_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.793262","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Munster P, Terzolo M et al (2022) Glucocorticoid receptor antagonism upregulates somatostatin receptor subtype 2 expression in ACTH-producing neuroendocrine tumors: new insight based on the selective glucocorticoid receptor modulator relacorilant. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.793262","journal-title":"Front Endocrinol"},{"key":"12915_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2023.100530","author":"K Bassil","year":"2023","unstructured":"Bassil K, Krontira A, Leroy T et al (2023) In vitro modeling of the neurobiological effects of glucocorticoids: a review. Neurobiol Stress. https:\/\/doi.org\/10.1016\/j.ynstr.2023.100530","journal-title":"Neurobiol Stress"},{"key":"12915_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225594","author":"BJ Mossakowska","year":"2022","unstructured":"Mossakowska BJ, Rusetska N, Konopi\u0144ski R et al (2022) The expression of cell cycle-related genes in USP8-mutated corticotroph neuroendocrine pituitary tumors and their possible role in cell cycle-targeting treatment. Cancers. https:\/\/doi.org\/10.3390\/cancers14225594","journal-title":"Cancers"},{"key":"12915_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115417","author":"E Merkouris","year":"2014","unstructured":"Merkouris E, Brasinika A, Patsiavoura M et al (2014) Molecular basis of anxiety: a comprehensive review of 2014\u20132024 clinical and preclinical studies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26115417","journal-title":"Int J Mol Sci"},{"key":"12915_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/1878-0261.13107","volume":"16","author":"S Pedraza-Ar\u00e9valo","year":"2021","unstructured":"Pedraza-Ar\u00e9valo S, Ib\u00e1\u00f1ez-Costa A, Bl\u00e1zquez-Encinas R et al (2021) Epigenetic and post\u2010transcriptional regulation of somatostatin receptor subtype 5 (SST5) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 16:764\u2013779. https:\/\/doi.org\/10.1002\/1878-0261.13107","journal-title":"Mol Oncol"},{"key":"12915_CR30","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej23-0007","author":"H Nishioka","year":"2023","unstructured":"Nishioka H (2023) Aggressive pituitary tumors (PitNETs). Endocr J. https:\/\/doi.org\/10.1507\/endocrj.ej23-0007","journal-title":"Endocr J"},{"key":"12915_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/17590914231181037","author":"N Ji","year":"2023","unstructured":"Ji N, Lei M, Chen Y, Tian S, Li C, Zhang B (2023) How Oxidative Stress Induces Depression? ASN Neuro. https:\/\/doi.org\/10.1177\/17590914231181037","journal-title":"ASN Neuro"},{"issue":"12","key":"12915_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"12915_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo AS, Lam HY et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"12915_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2611191","author":"Y Li","year":"2026","unstructured":"Li Y, Lu Y, Lin X, Zhao L (2026) The role of zinc homeostasis in major depressive disorder: heterogeneous pathological mechanisms and therapeutic implications. Ann Med. https:\/\/doi.org\/10.1080\/07853890.2025.2611191","journal-title":"Ann Med"},{"key":"12915_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1667459","author":"N Ay\u015fit","year":"2026","unstructured":"Ay\u015fit N, Altinta\u015f E, Alkan FK, Ozturk G, Korkaya H (2026) The neural niche in cancer: mechanistic insights into tumor\u2013neuron\u2013immune crosstalk and therapeutic opportunities. Frontiers in Cell and Developmental Biology. https:\/\/doi.org\/10.3389\/fcell.2026.1667459","journal-title":"Frontiers in Cell and Developmental Biology."},{"key":"12915_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123218","author":"G Di Muro","year":"2023","unstructured":"Di Muro G, Mangili F, Esposito E et al (2023) A \u03b2-Arrestin 2-biased dopamine receptor type 2 (DRD2) agonist is more efficacious than cabergoline in reducing cell proliferation in PRL-secreting but not in non-functioning pituitary tumor cells. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15123218","journal-title":"Cancers (Basel)"},{"key":"12915_CR37","doi-asserted-by":"publisher","DOI":"10.1530\/erc-25-0535","author":"D De Alcubierre","year":"2026","unstructured":"De Alcubierre D, Carbonara F, Feola T et al (2026) Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/erc-25-0535","journal-title":"Endocr Relat Cancer"},{"key":"12915_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27052449","author":"K Dynda\u0142","year":"2026","unstructured":"Dynda\u0142 K, Pa\u0144czyszyn-Trzewik P, Jakubowska B, Sowa-Ku\u0107ma M (2026) The role of exosomes in the regulation of molecular mechanisms underlying treatment resistance\u2014linking cellular crosstalk to clinical implications in depression. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms27052449","journal-title":"Int J Mol Sci"},{"issue":"4","key":"12915_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101910","volume":"38","author":"J MacFarlane","year":"2024","unstructured":"MacFarlane J, Korbonits M (2024) Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess. Best Pract Res Clin Endocrinol Metab 38(4):101910. https:\/\/doi.org\/10.1016\/j.beem.2024.101910","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"12915_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.06.019","author":"L Yu","year":"2021","unstructured":"Yu L, Wei J, Liu P (2021) Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.019","journal-title":"Semin Cancer Biol"},{"key":"12915_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-026-10402-7","author":"S Jayaraman","year":"2026","unstructured":"Jayaraman S, Eswaran A, Rajagopal P et al (2026) Neuroendocrine-associated epigenetic factors in cellular senescence: mechanisms and therapeutic implications. Biogerontology. https:\/\/doi.org\/10.1007\/s10522-026-10402-7","journal-title":"Biogerontology"},{"issue":"7","key":"12915_CR42","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acsptsci.4c00021","volume":"7","author":"L Xu","year":"2024","unstructured":"Xu L, Ning R, Du X et al (2024) Bone morphogenetic protein signaling agonist SB4 (BMPSB4) inhibits corticotroph pituitary neuroendocrine tumors by activation of autophagy via a BMP4\/SMADs-dependent pathway. ACS Pharmacol Transl Sci 7(7):1951\u20131970. https:\/\/doi.org\/10.1021\/acsptsci.4c00021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"24","key":"12915_CR43","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","volume":"65","author":"J Huang","year":"2022","unstructured":"Huang J, Chen L, Wu J et al (2022) Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions. J Med Chem 65(24):16033\u201316061. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01070","journal-title":"J Med Chem"},{"key":"12915_CR44","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1111\/ejn.15136","volume":"53","author":"R Subba","year":"2021","unstructured":"Subba R, Sandhir R, Singh SP, Mallick B, Monda AC (2021) Pathophysiology linking depression and type 2 diabetes: Psychotherapy, physical exercise, and fecal microbiome transplantation as damage control. Eur J Neurosci 53:2870\u20132900. https:\/\/doi.org\/10.1111\/ejn.15136","journal-title":"Eur J Neurosci"},{"key":"12915_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.611752","author":"F Mangili","year":"2021","unstructured":"Mangili F, Treppiedi D, Catalano R et al (2021) A novel mechanism regulating dopamine receptor type 2 signal transduction in pituitary tumoral cells: the role of cAMP\/PKA-induced filamin a phosphorylation. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2020.611752","journal-title":"Front Endocrinol"},{"key":"12915_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-025-02050-8","author":"I Nasi-Kordhishti","year":"2025","unstructured":"Nasi-Kordhishti I, Hladik M, Kandilaris K, Behling F, Honegger J, Schittenhelm J (2025) Transcription factor-based classification of pituitary adenomas \/ PitNETs: a comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-025-02050-8","journal-title":"Acta Neuropathol Commun"},{"key":"12915_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.crfs.2026.101372","author":"Y Su","year":"2026","unstructured":"Su Y, Xia Y (2026) Gut microbiota dysbiosis and depression: bidirectional interactions, mediating pathways, and microecological therapeutics. Curr Res Food Sci. https:\/\/doi.org\/10.1016\/j.crfs.2026.101372","journal-title":"Curr Res Food Sci"},{"key":"12915_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12959","author":"K Shiraishi","year":"2023","unstructured":"Shiraishi K, Akai T, Tomita T, Hayashi R, Minamisaka T, Kuroda S (2023) Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: a case report. Neuropathology. https:\/\/doi.org\/10.1111\/neup.12959","journal-title":"Neuropathology"},{"key":"12915_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","author":"Y He","year":"2021","unstructured":"He Y, Sun M, Zhang GG et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"key":"12915_CR50","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2021","unstructured":"Borgna F, Haller S, Rodr\u00edguez JM et al (2021) Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 49:1113\u20131126. https:\/\/doi.org\/10.1007\/s00259-021-05564-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12915_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-026-10876-5","author":"A Shadab","year":"2027","unstructured":"Shadab A, Haider MF, Abohassan M (2027) Lipid nanoparticles based drug delivery systems: design innovations, therapeutic applications, and translational progress. J Pharm Innov. https:\/\/doi.org\/10.1007\/s12247-026-10876-5","journal-title":"J Pharm Innov"},{"key":"12915_CR52","doi-asserted-by":"publisher","DOI":"10.34133\/research.0948","author":"B Huang","year":"2025","unstructured":"Huang B, An H, Wu H et al (2025) Chronic psychological stress in oncogenesis: multisystem crosstalk and multimodal interventions. Res. https:\/\/doi.org\/10.34133\/research.0948","journal-title":"Res"},{"key":"12915_CR53","doi-asserted-by":"publisher","DOI":"10.1055\/a-2795-7008","author":"SA Faiz","year":"2026","unstructured":"Faiz SA, Ansari A (2026) Translational Insights into Liposomal Drug Delivery: Recent Advances, Therapeutic Applications, and Clinical Trials. Drug Research. https:\/\/doi.org\/10.1055\/a-2795-7008","journal-title":"Drug Research"},{"key":"12915_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111055","author":"M Tufail","year":"2024","unstructured":"Tufail M, Wan W, Jiang C, Li N (2024) Targeting PI3K\/AKT\/mTOR signaling to overcome drug resistance in cancer. Chem Biol Interact. https:\/\/doi.org\/10.1016\/j.cbi.2024.111055","journal-title":"Chem Biol Interact"},{"key":"12915_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149239","author":"X Zhao","year":"2023","unstructured":"Zhao X, An X, Yang C, Sun W, Ji H, Lian F (2023) The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2023.1149239","journal-title":"Front Endocrinol"},{"key":"12915_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030501","author":"MC Cantone","year":"2021","unstructured":"Cantone MC, Dicitore A, Vitale G (2021) Somatostatin-dopamine chimeric molecules in neuroendocrine neoplasms. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10030501","journal-title":"J Clin Med"},{"key":"12915_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116850","author":"P Garg","year":"2025","unstructured":"Garg P, Ramisetty S, Nair M et al (2025) Strategic advancements in targeting the PI3K\/AKT\/mTOR pathway for breast cancer therapy. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2025.116850","journal-title":"Biochem Pharmacol"},{"key":"12915_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-026-03763-w","author":"J Zhang","year":"2026","unstructured":"Zhang J, Zhou Y, Mei X et al (2026) Molecular mechanisms and therapeutic potential of tryptophan metabolism in gut-brain signaling transduction: a narrative review. J Neuroinflammation. https:\/\/doi.org\/10.1186\/s12974-026-03763-w","journal-title":"J Neuroinflammation"},{"key":"12915_CR59","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.123.265706","volume":"65","author":"J Strosberg","year":"2024","unstructured":"Strosberg J, Al-Toubah T, El-Haddad G, Lagunes DR, Bodei L (2024) Sequencing of Somatostatin-Receptor\u2013Based Therapies in Neuroendocrine Tumor Patients. The Journal of Nuclear Medicine 65:340\u2013348. https:\/\/doi.org\/10.2967\/jnumed.123.265706","journal-title":"The Journal of Nuclear Medicine"},{"key":"12915_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/08977194.2026.2671736","volume":"44","author":"J Ye","year":"2026","unstructured":"Ye J, Wen Y, Zhan J et al (2026) The role of ERK signaling pathway in pituitary adenomas: from molecular mechanisms to targeted therapy. Growth Factors 44:77\u201393. https:\/\/doi.org\/10.1080\/08977194.2026.2671736","journal-title":"Growth Factors"},{"key":"12915_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01251-0","author":"J Guo","year":"2022","unstructured":"Guo J, Huang X, Dou L et al (2022) Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-022-01251-0","journal-title":"Signal Transduct Target Ther"},{"key":"12915_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-026-02225-x","author":"K Dalakas","year":"2026","unstructured":"Dalakas K, Engstr\u00f6m B, Tebani A et al (2026) Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-026-02225-x","journal-title":"Acta Neuropathol Commun"},{"key":"12915_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1708792","author":"D Sanchis-Pascual","year":"2025","unstructured":"Sanchis-Pascual D, G\u00f3mez CR, Morillas-Amat P et al (2025) Biological poisons targeting the pituitary gland: insights across the five kingdoms. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2025.1708792","journal-title":"Front Endocrinol"},{"key":"12915_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049109","author":"R Vergeer","year":"2021","unstructured":"Vergeer R, Postma M, Schmidt I et al (2021) Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2021-049109","journal-title":"BMJ Open"},{"issue":"17","key":"12915_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174093","volume":"14","author":"T Feola","year":"2022","unstructured":"Feola T, Carbonara F, Verrico M, Di Crescenzo RM, Gianno F, Colonnese C, Arcella A, de Alcubierre D, Tomao S, Esposito V, Giangaspero F, Minniti G, Jaffrain-Rea ML (2022) Immunotherapy for aggressive and metastatic pituitary neuroendocrine tumors (PitNETs): state-of-the art. Cancers (Basel) 14(17):4093. https:\/\/doi.org\/10.3390\/cancers14174093","journal-title":"Cancers (Basel)"},{"key":"12915_CR66","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.3390\/cimb46090578","volume":"46","author":"A Periferakis","year":"2024","unstructured":"Periferakis A, Tsigas G, Periferakis A et al (2024) Agonists, antagonists and receptors of somatostatin: pathophysiological and therapeutical implications in neoplasias. Curr Issues Mol Biol 46:9721\u20139759. https:\/\/doi.org\/10.3390\/cimb46090578","journal-title":"Curr Issues Mol Biol"},{"key":"12915_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70635","author":"N Kumari","year":"2026","unstructured":"Kumari N, Hoffmann P, Reichl L et al (2026) Epigenetic dysregulation of somatostatin receptors (SSTR) 1-5 and therapeutic implications in neuroendocrine and non-neuroendocrine malignancies. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.70635","journal-title":"Int J Cancer"},{"key":"12915_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-026-04508-0","author":"A Shadab","year":"2026","unstructured":"Shadab A, Al-shdefat RIK (2026) Redefining breast cancer: therapeutic opportunities in HER2-low and emerging molecular subtypes. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-026-04508-0","journal-title":"Clin Transl Oncol"},{"key":"12915_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241240316","author":"P Melhorn","year":"2024","unstructured":"Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, Raderer M, Kiesewetter B (2024) From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359241240316","journal-title":"Ther Adv Med Oncol"},{"key":"12915_CR70","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1007\/s00259-024-06639-4","volume":"51","author":"M Liu","year":"2024","unstructured":"Liu M, Cheng Y, Bai C et al (2024) Gallium-68 labeled somatostatin receptor antagonist PET\/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. Eur J Nucl Med Mol Imaging 51:2002\u20132011. https:\/\/doi.org\/10.1007\/s00259-024-06639-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12915_CR71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2022.09.009","volume":"176","author":"J Evans","year":"2022","unstructured":"Evans J, Beaumont J, Braga M et al (2022) Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. Eur J Cancer 176:110\u2013120. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.009","journal-title":"Eur J Cancer"},{"key":"12915_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1527083","author":"L Streit","year":"2025","unstructured":"Streit L, Tanguy \u00c9, Brunaud L et al (2025) Cellular mechanisms of hormone secretion in neuroendocrine tumors: what goes wrong? Frontiers in Cell and Developmental Biology. https:\/\/doi.org\/10.3389\/fcell.2025.1527083","journal-title":"Frontiers in Cell and Developmental Biology."},{"key":"12915_CR73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2522515122","author":"Y Li","year":"2025","unstructured":"Li Y, Xing Z, Hu W et al (2025) Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.2522515122","journal-title":"Proc Natl Acad Sci USA"},{"key":"12915_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14948","author":"J Zacharjasz","year":"2024","unstructured":"Zacharjasz J, Sztachera M, Smuszkiewicz M, Piwecka M (2024) Micromanaging the neuroendocrine system \u2013 a review on miR\u20107 and the other physiologically relevant miRNAs in the hypothalamic\u2013pituitary axis. FEBS Lett. https:\/\/doi.org\/10.1002\/1873-3468.14948","journal-title":"FEBS Lett"},{"key":"12915_CR75","doi-asserted-by":"publisher","first-page":"A576","DOI":"10.1210\/jendso\/bvac150.1195","volume":"6","author":"Y Zavros","year":"2022","unstructured":"Zavros Y, Mallick S, Chakrabarti J et al (2022) RF01 | PMON168 Hedgehog-induced somatostatin receptor expression is inhibited by the activation of the glucocorticoid receptor signaling pathway in human pituitary adenoma organoids. J Endocr Soc 6:A576\u2013A577. https:\/\/doi.org\/10.1210\/jendso\/bvac150.1195","journal-title":"J Endocr Soc"},{"key":"12915_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021331","author":"Z Saleh","year":"2024","unstructured":"Saleh Z, Moccia MC, Ladd ZA et al (2024) Pancreatic neuroendocrine tumors: signaling pathways and epigenetic regulation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25021331","journal-title":"Int J Mol Sci"},{"key":"12915_CR77","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/14737175.2024.2417419","volume":"25","author":"E Lauricella","year":"2024","unstructured":"Lauricella E, Vilisova S, Chaoul N et al (2024) The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives. Expert Rev Neurother 25:245\u2013258. https:\/\/doi.org\/10.1080\/14737175.2024.2417419","journal-title":"Expert Rev Neurother"},{"key":"12915_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178539","author":"Q Wang","year":"2025","unstructured":"Wang Q, Librizzi D, Bagheri S et al (2025) Theranostic radiopharmaceuticals of somatostatin receptors for patients with neuroendocrine tumors: agonists versus antagonists\u2014a systematic review and meta-analysis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26178539","journal-title":"Int J Mol Sci"},{"key":"12915_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-026-02660-2","author":"S Jang","year":"2026","unstructured":"Jang S, Jeong J, Huh W (2026) Activation of the pituitary adenylate cyclase-activating polypeptide type I receptor promotes neuroblastoma proliferation and migration through distinct G protein pathways. Cell Commun Signal. https:\/\/doi.org\/10.1186\/s12964-026-02660-2","journal-title":"Cell Commun Signal"},{"key":"12915_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1511348","author":"H Ungefroren","year":"2025","unstructured":"Ungefroren H, Randeva H, Lehnert H et al (2025) Crosstalk of TGF-\u03b2 and somatostatin signaling in adenocarcinoma and neuroendocrine tumors of the pancreas: a brief review. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2025.1511348","journal-title":"Front Endocrinol"},{"key":"12915_CR81","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1515\/jpem-2025-0148","volume":"38","author":"K Karag\u00f6z","year":"2025","unstructured":"Karag\u00f6z K, Eken E\u015e, K\u00fc\u00e7\u00fckali GK et al (2025) Surgical treatment and somatostatin experience in growth hormone-secreting pituitary macroadenoma due to novel AIP mutation. J Pediatr Endocrinol Metab 38:1103\u20131110. https:\/\/doi.org\/10.1515\/jpem-2025-0148","journal-title":"J Pediatr Endocrinol Metab"},{"key":"12915_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-026-04755-1","author":"S Shin","year":"2026","unstructured":"Shin S, Bikki S, Byrnes K, Bandyopadhyay B (2026) Ca2+ Signaling Enables Growth Hormone Secretion from Cultured Mice Pituitary Somatotrophs, Facilitating Outgrowth in Hypothalamic Neuron. Neurochem Res. https:\/\/doi.org\/10.1007\/s11064-026-04755-1","journal-title":"Neurochem Res"},{"key":"12915_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13418","author":"T Radomsky","year":"2024","unstructured":"Radomsky T, Anderson RC, Millar RP, Newton C (2024) Restoring function to inactivating G protein\u2010coupled receptor variants in the hypothalamic\u2013pituitary\u2013gonadal axis 1. J Neuroendocrinol. https:\/\/doi.org\/10.1111\/jne.13418","journal-title":"J Neuroendocrinol"},{"key":"12915_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.10.009","author":"L Streit","year":"2021","unstructured":"Streit L, Moog S, Hugel S et al (2021) Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2021.10.009","journal-title":"Cancer Lett"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12915-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:02:40Z","timestamp":1791961360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12915-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12915"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12915-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1714"}}